Stockscreener 앱 받기
3.565
1.52%
-0.055
시간 외 거래:
3.57
0.005
+0.14%
전일 마감가:
$3.62
열려 있는:
$3.58
하루 거래량:
537.43K
Relative Volume:
0.77
시가총액:
$238.59M
수익:
-
순이익/손실:
$-27.03M
주가수익비율:
-6.3661
EPS:
-0.56
순현금흐름:
$-23.97M
1주 성능:
+1.86%
1개월 성능:
+25.09%
6개월 성능:
-61.38%
1년 성능:
+85.68%
1일 변동 폭
$3.52
$3.66
1주일 범위
$3.41
$3.705
52주 변동 폭
$1.43
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
863 MITTEN ROAD, BURLINGAME, CA
CRVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
3.565 | 238.59M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharmaceuticals Inc (CRVS) deserves deeper analysis - uspostnews.com
CRVS Stock: More Upside For Corvus Pharmaceuticals Inc (NASDAQ: CRVS)? - Marketing Sentinel
Corvus Pharmaceuticals Inc [CRVS] Investment Appeal on the Rise - knoxdaily.com
Gaining Ground: Corvus Pharmaceuticals Inc (CRVS) Closes Lower at 3.50, Down -3.58 - DWinneX
Market Resilience: Corvus Pharmaceuticals Inc (CRVS) Finishes Strong at 3.38, Up 0.30 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
An analyst sees good growth prospects for Corvus Pharmaceuticals Inc (CRVS) - Sete News
Corvus Pharmaceuticals Inc (CRVS) deserves closer scrutiny - uspostnews.com
Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Gaine, Closing at 3.52 - DWinneX
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - EMEA Tribune
Corvus Pharmaceuticals Inc [CRVS] Investment Guide: What You Need to Know - knoxdaily.com
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - The Manila Times
Novel Atopic Dermatitis Treatment Shows Promise: Key Phase 1 Trial Results To Be Unveiled at Major Conference - Stock Titan
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - The Manila Times
Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com
Corvus Pharmaceuticals expands board with new director - Investing.com Australia
Corvus Pharmaceuticals Appoints New Director to Board - TipRanks
Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan
Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN
Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha
Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada
Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - Greenwich Time
Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India
Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq
CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter
Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times
New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):